Illumina (Nasdaq:ILMN) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ILMN Stoklara Genel Bakış

Illumina, Inc. genetik ve genomik analiz için Amerika Birleşik Devletleri, Singapur, Birleşik Krallık ve uluslararası alanda dizileme ve dizi tabanlı çözümler sunmaktadır.

Şirket hakkında

ILMN temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Kazançların yılda 75.56% oranında artması öngörülüyor

Risk Analizi

Risk kontrollerimizden ILMN için herhangi bir risk tespit edilmedi.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

NovaSeq X Series Expansion To Propel Growth Amid Global Economic Hurdles

US$149.23

5.2% undervalued

4.58%

Revenue growth p.a.

2 days ago

Illumina, Inc. Rakipler

Waters

NYSE:WAT

US$21.0b

West Pharmaceutical Services

NYSE:WST

US$21.6b

Avantor

NYSE:AVTR

US$17.1b

Mettler-Toledo International

NYSE:MTD

US$31.1b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Illumina
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$141.43
52 Haftanın En Yüksek Seviyesi	US$148.19
52 Haftanın En Düşük Seviyesi	US$89.00
Beta	1.15
11 Aylık Değişim	9.99%
3 Aylık Değişim	30.33%
1 Yıllık Değişim	1.01%
33 Yıllık Değişim	-65.50%
5 Yıllık Değişim	-53.26%
Halka arzdan bu yana değişim	622.10%

Son Haberler & Güncellemeler

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Aug 21

Recent updates

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Aug 21

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Jul 23

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Jul 01

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Jun 28

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Dec 21

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Dec 03

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Oct 24

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Oct 03

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Aug 22

The Big Trends: New Frontiers in Healthcare

Jul 13

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Jul 03

Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Jun 13

Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Apr 12

Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Mar 14

Are Investors Undervaluing Illumina, Inc. (NASDAQ:ILMN) By 38%?

Dec 30

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$221?

Dec 02

Hissedar Getirileri

	ILMN	US Life Sciences	US Pazar
7D	8.7%	-2.5%	-0.7%
1Y	1.0%	15.4%	32.5%

Getiri vs. Endüstri: ILMN geçen yıl % 17.6 oranında getiri sağlayan US Life Sciences sektörünün gerisinde kaldı.

Getiri vs Piyasa: ILMN geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ILMN's price volatile compared to industry and market?
ILMN volatility
ILMN Average Weekly Movement	6.1%
Life Sciences Industry Average Movement	8.7%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

İstikrarlı Hisse Senedi Fiyatı: ILMN son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ILMN 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1998	10,615	Jacob Thaysen	www.illumina.com

Illumina, Inc. Amerika Birleşik Devletleri, Singapur, Birleşik Krallık ve uluslararası alanda genetik ve genomik analizler için dizileme ve dizi tabanlı çözümler sunmaktadır. Core Illumina ve GRAIL segmentleri aracılığıyla faaliyet göstermektedir. Şirket, reaktifler, akış hücreleri ve kütüphane hazırlamayı içeren dizileme ve dizi tabanlı cihazlar ve sarf malzemeleri; çeşitli boyut ve karmaşıklıktaki tüm genomları dizileyen tüm genom dizileme kitleri ve ekzomları, belirli genleri ve RNA'yı veya ilgilenilen diğer genomik bölgeleri dizileyen hedefli yeniden dizileme kitleri sunmaktadır.

Illumina, Inc. Temel Bilgiler Özeti

Illumina'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ILMN temel i̇stati̇sti̇kler
Piyasa değeri	US$21.72b
Kazançlar(TTM)	-US$3.04b
Gelir(TTM)	US$4.43b

5.1x

P/S Oranı

-7.4x

F/K Oranı

ILMN aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ILMN gelir tablosu (TTM)
Gelir	US$4.43b
Gelir Maliyeti	US$1.49b
Brüt Kâr	US$2.94b
Diğer Giderler	US$5.98b
Kazançlar	-US$3.04b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-19.11
Brüt Marj	66.34%
Net Kâr Marjı	-68.73%
Borç/Özkaynak Oranı	155.6%

ILMN uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ILMN Stoklara Genel Bakış

Ödüller

Risk Analizi

NovaSeq X Series Expansion To Propel Growth Amid Global Economic Hurdles

Illumina, Inc. Rakipler

NYSE:WAT

US$21.0b

NYSE:WST

US$21.6b

NYSE:AVTR

US$17.1b

NYSE:MTD

US$31.1b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Illumina, Inc. Announces Executive Changes

European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL

Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Consensus EPS estimates upgraded to US$9.60 loss

Now 23% overvalued after recent price rise

Recent updates

Illumina, Inc. Announces Executive Changes

European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL

Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Consensus EPS estimates upgraded to US$9.60 loss

Now 23% overvalued after recent price rise

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Illumina Launches New Oncology Menu for NovaSeq X Series Customers

Consensus EPS estimates fall from profit to US$1.71 loss

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Consensus EPS estimates upgraded to US$0.93 loss

Illumina, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Value

Now 24% overvalued

Illumina Launches Latest Chemistry Across Most Popular Mid-Throughput Sequencers, Enabling Higher Quality and Greater Speed for Customers at Lower Cost

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

Illumina, Inc. Appoints Anna Richo to its Board of Directors

Now 22% overvalued

Illumina: Expect A Slow Rebound

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Consensus EPS estimates fall by 25%

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Consensus EPS estimates upgraded to US$0.56 loss

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

CEO & Director recently bought US$992k worth of stock

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Consensus EPS estimates fall by 64%

Consensus EPS estimates upgraded to US$0.41 loss, revenue downgraded

Full year 2023 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc

Now 20% undervalued after recent price drop

Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc

Price target decreased by 15% to US$168

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Carl Icahn Accuses Board and Ex-CEO of Illumina Inc

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties

Price target decreased by 9.4% to US$203

EU Orders Illumina to Sell Cancer Testing Firm Grail

Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team